M
Michael Beck
Researcher at University of Mainz
Publications - 194
Citations - 10393
Michael Beck is an academic researcher from University of Mainz. The author has contributed to research in topics: Fabry disease & Enzyme replacement therapy. The author has an hindex of 56, co-authored 193 publications receiving 9528 citations. Previous affiliations of Michael Beck include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)
James E. Wraith,Lorne A. Clarke,Michael Beck,Edwin H. Kolodny,Gregory M. Pastores,Joseph Muenzer,David M. Rapoport,Kenneth I. Berger,Stuart J. Swiedler,Emil D. Kakkis,Tanja Braakman,Elenie Chadbourne,Karen Walton-Bowen,Gerald F. Cox +13 more
TL;DR: In patients with MPS I, laronidase significantly improves respiratory function and physical capacity, reduces glycosaminoglycan storage, and has a favorable safety profile.
Journal ArticleDOI
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
Paul Harmatz,Roberto Giugliani,Ida Vanessa Doederlein Schwartz,Nathalie Guffon,Elisa Leão Teles,M. Clara Sá Miranda,J. Edmond Wraith,Michael Beck,Laila Arash,Maurizio Scarpa,Zi-Fan Yu,Janet Wittes,Kenneth I. Berger,Mary S. Newman,Ann M. Lowe,Emil D. Kakkis,Stuart J. Swiedler +16 more
TL;DR: rhASB significantly improves endurance, reduces GAG, and has an acceptable safety profile, which is generally safe and well tolerated.
Journal ArticleDOI
Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.
Aleš Linhart,Christoph Kampmann,José Luis Zamorano,Gere Sunder-Plassmann,Michael Beck,Atul Mehta,Perry M. Elliott +6 more
TL;DR: The disease burden in treated women exceeds that of untreated men, suggesting that most women selected for ERT have advanced disease, and the presence of LVH is associated with higher frequency of cardiac signs and symptoms.
Journal ArticleDOI
Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Lorne A. Clarke,J. Edmond Wraith,Michael Beck,Edwin H. Kolodny,Gregory M. Pastores,Joseph Muenzer,David M. Rapoport,Kenneth I. Berger,Marisa Sidman,Emil D. Kakkis,Gerald F. Cox,Gerald F. Cox,Gerald F. Cox +12 more
TL;DR: This trial demonstrates the long-term clinical benefit and safety of laronidase in attenuated patients with mucopolysaccharidosis I and highlights the magnitude and chronology of treatment effects.
Journal ArticleDOI
Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)
Rick A. Martin,Michael Beck,Christine M. Eng,Roberto Giugliani,Paul Harmatz,Verónica Muñoz,Joseph Muenzer +6 more
TL;DR: A concise review of mucopolysaccharidosis II is provided for practitioners with the hope that such information will help identify affected boys earlier in the course of their disease.